3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
26
Breast Neoplasms
21
Carcinoma, Non-Small-Cell Lung
19
Lung Neoplasms
15
Head and Neck Neoplasms
13
Rectal Neoplasms
11
Colonic Neoplasms
11
Prostatic Neoplasms
8
Pancreatic Neoplasms
7
Mouth Neoplasms
6
Glioblastoma
6
Neuroblastoma
5
Neoplasm Metastasis
5
Esophageal Neoplasms
5
Central Nervous System Neoplasms
5
Carcinoma
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Triple Negative Breast Neoplasms
4
Recurrence
4
Precancerous Conditions
4
Ovarian Neoplasms
4
Oropharyngeal Neoplasms
4
Neoplasms
4
Liver Neoplasms
4
Laryngeal Neoplasms
4
Hypopharyngeal Neoplasms
4
Gliosarcoma
4
Carcinoma, Hepatocellular
4
Adenomatous Polyposis Coli
4
Sarcoma
3
Interventions
Capecitabine
6
Irinotecan
5
Fluorouracil
5
Cisplatin
5
Oxaliplatin
4
Leucovorin
4
Gemcitabine
4
apatinib
3
Sorafenib
3
Bevacizumab
3
tislelizumab
2
pembrolizumab
2
Sunitinib
2
Radiotherapy
2
Paclitaxel
2
Immune Checkpoint Inhibitors
2
Cyclophosphamide
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
regorafenib
1
pyrotinib
1
pemigatinib
1
lutetium Lu 177 dotatate
1
huachansu
1
halofantrine
1
guadecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Digestive System Neoplasms
×
Celecoxib
×
Clear all
NCT00808743
2013-05-16
PreDuoFAP
Radboud University Medical Center
Phase 2/3
Completed
37 enrolled